Gefitinib
Who holds supplier records for Gefitinib? 16 organisations hold a current record for Gefitinib: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 12 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (7), China (6), Netherlands (1), Taiwan (1) and 1 other country (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Gefitinib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/gefitinib
Reading the evidence
- 16 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 10 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (16)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Gefitinib. Country is the organisation's recorded country, not necessarily the manufacturing site.
- MSN Laboratories Private LimitedIndiaCEP Company GMP cert on recordActive DMF 39761, 29670 · latest filing Mar 2024
- Alembic Pharmaceuticals LimitedIndiaCEP Company GMP cert on recordActive DMF 30868 · latest filing Sept 2016
- Cipla LimitedIndiaCEP Company GMP cert on recordActive DMF 29090 · latest filing Mar 2015
- Hetero Labs LimitedIndiaCEP Company GMP cert on recordActive DMF 32274 · latest filing Dec 2017
- Natco PharmaIndiaCEP Company GMP cert on recordActive DMF 32409 · latest filing Jul 2018
- Shandong Anhong Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on recordActive DMF 29772 · latest filing Sept 2015
- SynthonNetherlandsCEP Company GMP cert on recordActive DMF 29797 · latest filing Nov 2015
- Wisdom Pharmaceutical Co., LtdChinaCEPActive DMF 41343 · latest filing Mar 2025
- Zhejiang Jiuzhou Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on recordActive DMF 30518 · latest filing Apr 2016
- CDYMAX (INDIA) PHARMA PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 40456 · latest filing Sept 2024
- SCINOPHARM TAIWAN LTDTaiwanActive DMF 31941 · latest filing Aug 2017
- Sichuan Xieli Pharmaceutical Co LtdChinaActive DMF 26456 · latest filing Sept 2012
- Yabao Pharmaceutical Group Co., Ltd.ChinaActive DMF 28613 · latest filing Sept 2014
- SpainCEP
- IndiaCEP
- ChinaCEP Company GMP cert on record
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (12)
Certificates of Suitability on the EDQM register for Gefitinib, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 15 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| MSN LABORATORIES PRIVATE LIMITED Kandi Mandal | IN | CEP 2025-590 - Rev 00 Gefitinib, Route code-GNB, micronised and non-micronised | Mar 2026 | Inspected Aug 2026 Slovakia |
| SAKAR HEALTHCARE LIMITED Ahmedabad | IN | CEP 2024-578 - Rev 00 Gefitinib | Feb 2026 | — |
| NATCO PHARMA LIMITED Hyderabad | IN | CEP 2017-244 - Rev 03 Gefitinib, Micronised | Feb 2026 | — |
| SYNTHON B.V. Nijmegen | NL | CEP 2016-154 - Rev 01 Gefitinib, Micronised | Dec 2025 | Inspected May 2024 Netherlands |
| HETERO LABS LIMITED Hyderabad | IN | CEP 2018-031 - Rev 02 Gefitinib | Aug 2025 | — |
| ZHEJIANG JIUZHOU PHARMACEUTICAL CO. LTD. Taizhou | CN | CEP 2018-236 - Rev 02 Gefitinib | Jun 2025 | Inspected Nov 2025 Hungary |
| CIPLA LIMITED Mumbai | IN | CEP 2017-002 - Rev 01 Gefitinib, Micronised | May 2025 | — |
| SHANDONG ANHONG PHARMACEUTICAL CO., LTD. Dezhou City | CN | CEP 2017-028 - Rev 01 Gefitinib | Apr 2024 | Inspected Nov 2025 Greece |
| ALEMBIC PHARMACEUTICALS LIMITED Vadodara | IN | CEP 2018-087 - Rev 01 Gefitinib, Form-I | Apr 2024 | — |
| WISDOM PHARMACEUTICAL CO., LTD. Haimen | CN | CEP 2022-291 - Rev 00 Gefitinib | Apr 2024 | — |
| ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. Linhai | CN | R1-CEP 2016-241 - Rev 00 Gefitinib | Nov 2022 | — |
| Farmhispania, S.A. Montmeló | ES | R1-CEP 2016-305 - Rev 00 Gefitinib | Oct 2022 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (1)
Organisations whose Type II DMFs for Gefitinib are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- China · Inactive DMF 27310 · filed Jul 2013
Overview
Gefitinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL939).
Chemical identity
- IUPAC name
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
- Canonical SMILES
- COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
- InChIKey
- XGALLCVXEZPNRQ-UHFFFAOYSA-N
- Synonyms
- Gefitinib, Gefitinib mylan, Iressa, NSC-759856, ZD-1839, ZD1839, Irressat, ZD 1839, gefitinibum, CHEBI:49668, NSC715055, RefChem:58462
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Kinase Inhibitor
- Mechanism of action
- Protein Kinase Inhibitors
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Gefitinib?
16 organisations hold an active US FDA Type II Drug Master File or a CEP for Gefitinib: MSN Laboratories Private Limited (India), Alembic Pharmaceuticals Limited (India), Cipla Limited (India), Hetero Labs Limited (India), Natco Pharma (India), Shandong Anhong Pharmaceutical Co., Ltd. (China), Synthon (Netherlands) and Wisdom Pharmaceutical Co., Ltd (China), and 8 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Gefitinib Drug Master Files are active?
MSN Laboratories Private Limited (DMF 39761, 29670), Alembic Pharmaceuticals Limited (DMF 30868), Cipla Limited (DMF 29090), Hetero Labs Limited (DMF 32274), Natco Pharma (DMF 32409), Shandong Anhong Pharmaceutical Co., Ltd. (DMF 29772), Synthon (DMF 29797) and Wisdom Pharmaceutical Co., Ltd (DMF 41343) and 5 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Gefitinib records mean?
1 organisation has only inactive Type II DMFs for Gefitinib. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Gefitinib have a European Certificate of Suitability?
Yes. 12 organisations hold a valid CEP for Gefitinib on the EDQM register, including MSN LABORATORIES PRIVATE LIMITED Kandi Mandal (IN), SAKAR HEALTHCARE LIMITED Ahmedabad (IN), NATCO PHARMA LIMITED Hyderabad (IN), SYNTHON B.V. Nijmegen (NL), HETERO LABS LIMITED Hyderabad (IN) and ZHEJIANG JIUZHOU PHARMACEUTICAL CO. LTD. Taizhou (CN) and 6 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Gefitinib supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Gefitinib?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.